-

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at four upcoming investor conferences (all times below are in Eastern Time):

  • The SVB Leerink 9th Annual Global Healthcare Conference in New York City, NY on Thursday, February 27, 2020 at 9:00 a.m.
  • The Cowen & Co. 40th Annual Health Care Conference in Boston, MA on Monday, March 2, 2020 at 1:30 p.m.
  • The Raymond James & Associates’ 41st Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2020 at 11:00 a.m.
  • The Barclays Global Healthcare Conference 2020 in Miami, FL on Wednesday, March 11, 2020 at 3:20 p.m.

To listen to live audio webcasts of the presentations, please visit http://investors.insulet.com. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.omnipod.com.

Contacts

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Michael True
Senior Manager, Investor Relations
(978) 600-7226
mtrue@insulet.com

Media:
Angela Wiczek, Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Insulet Corporation

NASDAQ:PODD

Release Versions

Contacts

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Michael True
Senior Manager, Investor Relations
(978) 600-7226
mtrue@insulet.com

Media:
Angela Wiczek, Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

More News From Insulet Corporation

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omn...

Insulet Reports First Quarter 2026 Results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company’s guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4...

Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of...
Back to Newsroom